ReviewFrontiers in cardiovascular medicine2021
Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 64 citations in OpenAlex.
- CardioMorph Atlas: a statistical approach to evaluate association between pulmonary tuberculosis and cardiac morphology from chest X-rays.EBioMedicine · 2026Article
- Effect of the geometry and severity of left ventricular hypertrophy on cardiovascular mortality in dialysis patients.Kidney research and clinical practice · 2026Article
- Targeting the PI3K/Akt/mTOR and Nrf2 signaling axis with berberine: a novel strategy for attenuating diabetic cardiomyopathy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Prognostic Impact of Cardiorespiratory Fitness on Mortality in Diabetes Patients With and Without Left Ventricular Hypertrophy.Reviews in cardiovascular medicine · 2026Article
- Comparative predictive value of three non-insulin-based insulin resistance indices for subclinical left ventricular dysfunction in type 2 diabetes mellitus.BMC cardiovascular disorders · 2026Article
- Prognostic value of left ventricular phenotypes by cardiac magnetic resonance in elderly and non-elderly patients.Journal of geriatric cardiology : JGC · 2026Article
- Synergistic combination of taxifolin and baicalein protects against alloxan-induced diabetic cardiomyopathy by mitigating oxidative stress through the Nrf2/HO-1 signaling pathway.American journal of translational research · 2026Article
- The Contribution of Echocardiography to the Diagnosis and Prognosis Stratification of Diabetic Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2025Review
- Cardiac digital twins: a tool to investigate the function and treatment of the diabetic heart.Cardiovascular diabetology · 2025Review
- Multi-modal analyses of proteomic measurements associated with type 2 diabetes from the Project Baseline Health Study.Communications medicine · 2025Article
- ALDH2 Enzyme Deficiency in Diabetic Cardiomyopathy.International journal of molecular sciences · 2025Review
- Heart Rate Variability, Microvascular Dysfunction, and Inflammation: Exploring the Potential of taVNS in Managing Heart Failure in Type 2 Diabetes Mellitus.Biomolecules · 2025Review
- Endothelial Markers in Type 2 Diabetic Patients with Acute Decompensated Heart Failure: A Pilot Study.Metabolites · 2025Article
- Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study.BMC cardiovascular disorders · 2025Article
- Effects of exercise intensity and diet on cardiac tissue structure and FGF21/β-Klotho signaling in type 2 diabetic mice: a comparative study of HFD and HFD + STZ induced type 2 diabetes models in mice.Diabetology & metabolic syndrome · 2025Article
- Interaction between mitochondrial oxidative stress and myocardial fibrosis in the context of diabetes.Frontiers in endocrinology · 2025Review
- Advances in the Insulin-Heart Axis: Current Therapies and Future Directions.International journal of molecular sciences · 2024Review
- The nutrient sensor CRTC and Sarcalumenin/thinman represent an alternate pathway in cardiac hypertrophy.Cell reports · 2024Article
- Association between serum β2-microglobulin and left ventricular hypertrophy in patients with type 2 diabetes mellitus: A cross-sectional study.Journal of diabetes · 2024Article
- Molecular Basis of Cardiomyopathies in Type 2 Diabetes.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Heart failure is an important manifestation of diabetic heart disease. Before the development of symptomatic heart failure, as much as 50% of patients with type 2 diabetes mellitus (T2DM) develop asymptomatic left ventricular dysfunction including left ventricular hypertrophy (LVH). Left ventricular hypertrophy (LVH) is highly prevalent in patients with T2DM and is a strong predictor of adverse cardiovascular outcomes including heart failure. Importantly regression of LVH with antihypertensive treatment especially renin angiotensin system blockers reduces cardiovascular morbidity and mortality. However, this approach is only partially effective since LVH persists in 20% of patients with hypertension who attain target blood pressure, implicating the role of other potential mechanisms in the development of LVH. Moreover, the pathophysiology of LVH in T2DM remains unclear and is not fully explained by the hyperglycemia-associated cellular alterations. There is a growing body of evidence that supports the role of inflammation, oxidative stress, AMP-activated kinase (AMPK) and insulin resistance in mediating the development of LVH. The recognition of asymptomatic LVH may offer an opportune target for intervention with cardio-protective therapy in these at-risk patients. In this article, we provide a review of some of the key clinical studies that evaluated the effects of allopurinol, SGLT2 inhibitor and metformin in regressing LVH in patients with and without T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.